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ABSTrACT                        Our immune system, fine-tuned by a long evolution, has a near-infinite capacity 
to recognize potential pathogens and mutant self proteins. It has also got a varied arsenal of 
killing mechanisms to battle intruders and mutant cells. Since malignant transformation involves 
1) mutations of proteins of various classes and 2) over-expression of non-altered genes, either 
related or unrelated to the oncogenic process, the adaptive immune system has the potential 
to recognize and clear malignantly transformed cells. Immunotherapeutic interventions might 
1) trigger an immune response to otherwise tolerated tumor antigens, 2) enhance the existing, 
but insufficient anti-tumor immune response, add new receptors, recombinant antibodies or 
T cell receptors, to the system, or 4) rely on the transfer of ex vivo expanded immune effector 
cells. Although tumor immunotherapy is decades-old, immune checkpoint inhibitor therapy, 
probably the most significant breakthrough, is a development of the last few years. Reaching 
its maturity, tumor immunotherapy is just now becoming an integral part of tumor therapy.
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Immune surveillance, pro and contra
Immune surveillance is the body’s ability to recognize and 
eliminate neoplastic cells. Although it seems to be self-
evident, this notion is less than sixty years old. The concept 
of immune surveillance was raised by Burnet (1957). An 
obvious argument prompting the original hypothesis was that 
immunosuppressed and immunodeficient individuals have 
an increased incidence of certain types of tumors, mostly 
skin cancers and leukemia. The situation is, however, more 
complex than this simplified theory would suggest.
Quite a few immunologists have always been criticizing 
the concept as controversial. Numerous observations point 
out that immunosurveillance might not be an utterly effective, 
neither universal, anti-tumor mechanism. Immunodeficient 
mice, for example, are not known to have a particularly ele-
vated frequency of malignant tumors (except for tumors of 
the hematopoietic system). Since the life span of a laboratory 
mouse is less than two years, one can argue that this model is 
not relevant when compared to long living mammals, includ-
ing humans. 
Human epidemiological data are also intriguing: although 
the examples of skin tumors and leukemias are frequently 
cited, other types of tumors do not seem to be more frequent 
in immunosuppressed patients. For many years, no synthesis 
of these conflicting theories was provided.
The only large-scale meta-analysis of the field compared 
tumor incidence (relative risk) in normal controls and two 
immunosuppressed patient groups: organ transplant recipients 
who are treated with Cyclosporine A, an immunosuppres-
sive drug that prevents T cell activation, and HIV infected 
individuals with overt AIDS, i.e., clinically manifest immu-
nosuppression (de Visser et al. 2006). The effect of immu-
nosuppression on tumor incidence varied, depending on the 
tumor type. Some types of tumors, like cutaneos tumors, non-
Hodgkin lymphoma, or cervical carcinoma, indeed become 
much more frequent (relative risks: 16-70, 24-30 and 5-9). 
Importantly, these tumor types are well known examples of 
highly immunogenic, most frequently virus (typically HPV) 
induced malignancies. Surprisingly, other cancer types, as 
breast, prostate-, bladder-, ovarian or uterine cancers, had a 
drastically decreased incidence (relative risks between 0.28 
and 0.8). These results point to a paradoxical, tumor support-
ing role of the immune system (de Visser et al. 2006).
Tumor immunotherapy, however, provides an indirect 
proof of the importance of immune surveillance. By enhan-
cing the existing, but weak T cell response by CTLA-4 or 
PD-1 inhibitors, a “latent” immune response is revealed in 
a considerable fraction of different malignancies (Weber 
2010). 
On the other hand, immunoediting, the phenomenon when 
the anti-tumor immune response shapes the evolution of can-
cer, is another example when the latent anti-tumor response 
becomes visible (Dunn et al. 2002).
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In conclusion, immune surveillance might protect us from 
some types of neoplasms, but it is neither universal, nor infal-
lible. On the other hand, manipulation of the immune system 
by immunization or biological response modifiers might 
induce an effective immune response even in cases when the 
effectiveness of the „natural” immune response is insufficient. 
Adoptive transfer of ex vivo activated or expanded immune 
cells, recombinant immunoglobulins or further, new genera-
tion, immune recognition molecules, as bi-specific antibodies, 
likewise provides new tools for cancer immunotherapy.
Danger signals and tumors
One of the central concepts in modern immunology is danger 
hypothesis. The term was coined in the nineties by one of 
the most influential immunologists of the recent years, Polly 
Matzinger (1994). The adaptive immune system is able to 
recognize even single amino acid differences, effectively 
differentiating self- and non-self molecules. However, the 
adaptive immune system, too dangerous because of its in-
herent potential of auto-reactivity, is under the control of the 
more dependable innate immune system. The first step of 
any immune response is the „validation” of the presence of a 
noxious intruder, i.e., „danger”.
Phagocytes, the first line of defense against intruders, can 
be triggered by different mechanisms. Particles that have a 
diameter similar to viruses or bacteria trigger phagocytosis 
independently of their surface properties. According to a 
recent seminal paper, the deformation of the cell membrane, 
as detected via the membrane anchored cytoskeleton, pro-
vides the decisive signal (Champion and Mitragotri 2006). 
Phagocytosis alone is not an „immunogenic” procedure; the 
processes that destroy the phagocytosed particle must be 
activated by pattern recognition receptors, otherwise, phago-
cytosis is immunologically “silent”. This recognition might 
take place either on the outer surface of the cell membrane, 
or on the inner surface of the phagosome.
Several arrays of phagocytotic and pattern recognition 
receptors play role in the process. Mannose receptors are 
C type lectins that detect carbohydrates absent in the mam-
malian cell membrane, but frequently present on the surface 
of microorganisms. Scavenger receptors are a distinct set of 
cell surface proteins of unusual trimeric structure. Beside 
their defining target structures, oxidized or native low density 
lipoprotein (LDL), they recognize a wide array of pathogen 
associated molecular patterns. The most important „danger” 
receptors are, however, toll-like receptors (TLR). TLRs cover 
a wide array of pathogen- or cell-stress signals (Janeway and 
Medzhitov 2002). The double stranded RNA of viruses is 
recognized by TLR3, the lipopolysaccharide (LPS) cell wall 
of Gram-positive bacteria by TLR4, the lipoteichoic acid of 
Gram-negative bacteria by TLR2, the cilia and flagellae of 
bacteria by TLR5, the non methylated CpG sequences of 
bacterial DNA, as well as the mannanes of fungi by TLR9. A 
further distinct family of danger receptors is the nucleotide-
binding oligomerization domain receptor (NLR) family. They 
are intracellular pattern recognition receptors that cooperate 
with TLR in detecting danger (Maekawa et al. 2011).
Since they are mostly analogous to normal tissues, at 
first sight, tumors do not seem to present danger signals to 
the innate immune system. Fortunately, this statement is not 
entirely valid. The abnormally high cell division rate and 
protein over-expression, typical for most tumors, can result 
in cell stress. Chaperones induced by cellular stress then may 
act as danger signals. In addition, angiogenesis can not always 
keep pace with the rate of proliferation of the malignant cells, 
resulting in anoxia, metabolic acidification, and, eventually, 
necrosis inside the tumor mass. An important feature of 
malignant tumors is genetic heterogeneity. The genetically 
different tumor sub-clones then compete with each other for 
the limited resources, so some of the sub-clones starve, others 
thrive (Merlo 2006). 
IL-1α and its homologue IL-18 are major regulators of 
the inflammatory immune response. They are stored in the 
cytoplasm of diverse cell types as inactive precursors lacking 
signal peptide. Proteolytic enzymes of dying cells release ac-
tive IL-1α and IL-18, triggering a signal pathway overlapping 
with those of TLR (Watanabe and Kobayashi 1994; Franchi 
et al. 2009; van de Veerdonk et al. 2011). 
Heat shock proteins, i.e., chaperones overproduced in tu-
mor cells stressed by disturbances of the regulation of protein 
synthesis, or by “starving” inside an overgrown tumor mass, 
are also TLR targets activating the immune system. The best 
example of this type of interaction is recognition of HSP70 
by TLR4 on immune cells (Juhasz et al. 2013).
Since they are normally buried inside the cells, otherwise 
“physiologic” hydrophobic intracellular structures (“Hyp-
pos”) exposed to immune cells in case of cell damage, includ-
ing necrosis inside the tumor mass, are also stress signals 
(Seong and Matzinger 2004).
NK-T cells and cell stress
NK-T cells share the characteristics of the two cell types. 
Along with receptors typically associated with NK cells, 
they express a low diversity T cell receptor (Vα24-Jα18:Vα11) 
that detects a single target, a stress signal. This stress signal 
is a membrane lipid component, α-GalCer, presented on a 
(practically) monomorphic MHC family member, the CD1d 
molecule. Besides their effector function, NK-T cells are 
major source of cytokines, acting as key regulators of the 
immune response. Their therapeutic manipulation, either by 
their natural ligands, or by other methods, offers new pos-




Effector functions of immunoglobulin isotypes
Neutralization is a function shared by all immunoglobulin 
isotypes, and it is the only effector function of the IgG4 iso-
type. Monoclonal antibodies may behave as receptor agonists 
or antagonists. Receptor antagonist antibodies may block the 
signals of cell surface growth factor receptors of tumor cells. 
On the other hand, they may likewise block the signals of 
negative immune response regulators of immune cells. Both 
possibilities are exploited in tumor therapy. On the other 
hand, receptor agonist antibodies may be used to activate 
co-stimulatory immune cell receptors. As we see later, this 
approach failed in the first Phase 1 clinical trial, however, 
theoretically it might still be viable. An important aspect of 
the receptor agonist therapy is that the targeted immune cells 
should survive the contact with the antibody. Because of that, 
IgG4 antibodies, which do not bind Fc receptors, nor activate 
the complement system, are the best choice in these cases. 
Antibody Dependent Cellular Cytotoxicity (ADCC) is a 
function of NK cells recognizing cell-bound IgG molecules 
via Fc receptors. NK cells might be able to kill malignant 
cells recognizing cell stress markers or gene products of 
oncogenic viruses. NK killing, however, is much more ef-
fective if the target cells are „marked” with Fc receptor 
binding antibodies. ADCC is a major mechanism of action 
of therapeutic antibodies (Cooley et al. 1999). Phagocytosis 
of cells “opsonized” by cell surface IgG is also triggered by 
Fc receptors of macrophages. Importantly, IgG1 is the most 
efficient IgG isotype for triggering both ADCC and phago-
cytosis. Complement dependent cell lysis (CDC) can also 
kill antibody-marked tumor cells. From the IgG isotypes, 
IgG1 is the most effective in eliciting the classical pathway 
of complement activation as well.
Taken together, IgG1 is the best choice if the goal is tumor 
cells’ elimination, while IgG2 or IgG4 are the right choices 
if the goal is immune cell activation. Importantly, not only 
the isotype, but glycosylation pattern of the immunoglobu-
lins influences the target killing, with non-fucosylated IgG1 
antibodies being the most efficient (Jefferis 2007).
Multi-step carcinogenesis provides multiple 
targets for tumor immunotherapy
Carcinogenesis is not the result of a single mutation; it is 
rather a multi-step process (Hanahan and Weinberg 2000). 
Loss of genetic stability is one of the necessary genetic altera-
tions, enabling accelerated “collection” of harmful genetic 
changes. Until genetic stability is lost, only mutant oncogenes 
and the up-regulated differentiation antigens provide targets 
to the immune system. From the point when genetic stability 
is lost, „bystander mutations”, i.e., mutations which are not 
necessary for maintaining the malignant phenotype, keep 
collecting. As a result, a considerable part of the genome is 
altered, providing a rich array of potential immune targets. 
Some of these targets are unique to the individual tumors, 
like individual point mutations in signal proteins; others are 
either tissue-specific or specific to a class of tumors. These 
„shared” tumor-associated antigens are the most promising 
targets of anti-tumor immunotherapy. Besides the lack of 
danger signals, tumor-induced immunomodulation is the main 
obstacle hindering the generation of an effective anti-tumor 
immune response (Zou 2005; De Visser 2006; Marton et al. 
2012; Sica and Mantovani 2012).
T and B cell receptor epitopes of tumor 
associated antigens
The evolutionary role of MHC-I is „exposing” the internal 
composition of the cell to the T cells searching for intruders. 
Together with the “normal” intracellular peptide repertoire, 
MHC-I presents viral proteins, as well as mutant self pro-
teins, including potential tumor antigens. MHC-II, on the 
other hand, presents peptides derived from phagocytosed 
proteins by digestion in the phago-lysosome. The evolution-
ary role of MHC-II is „sampling” the internal environment 
for signatures of eventual pathogens, and transporting them 
to the lymph node, where the information exchange between 
the phagocytes (sentinels) and naive and activated effectors 
takes place. Cross-presentation is the process when not only 
endogenous, but phagocytosed proteins are presented on 
MHC-I of professional antigen presenting cells. The main 
mechanism of cross-presentation is ER-phagosome fusion 
occurring shortly after the phagosome formation (Heath and 
Carbone 2001). While only leukemias/lymphomas express 
MHC-II, all tumors express MHC-I, therefore, they may all 
be targets of CD8+ cytotoxic T cells.
Cell surface molecules of tumors may serve as targets of 
antibodies; therefore their detection is relatively straightfor-
ward. More complex efforts are required for the discovery 
of T cell antigens of tumors, requiring primary tumor cell 
culture, primary T cell culture, creation of tumor cDNA 
banks, transfection and high throughput functional screening 
of immune recognition. The established T cell clones can be 
used to screen tumor antigen libraries, i.e., MHC-identical 
non-malignant antigen presenting cells transfected with 
cDNA banks from the tumor cells used to generate the T cell 
clones (Boon et al. 1997). The read-out might be cytotoxicity, 
T cell proliferation or cytokine production. The discovered 
tumor antigens belong to several classes. An exhaustive list 
of the known tumor antigens is presented in the review of 
Novellino et al. (2005).
Mutant oncogens, such as the P53 tumor suppressor pro-
tein point mutants, are frequent in certain types of tumors. 
Mutant P53 was indeed shown to be targeted by tumor-
specific CTL.
Differentiation antigens overproduced in specific tissue 
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types, as well as tumors originating from the same tissue 
might also serve as targets of an anti-tumor immune response. 
For example, tyrosinase and other enzymes of the melanin 
biosynthesis are potential targets of an anti-melanoma im-
mune response. In accordance with that, vitiligo due to 
melanocyte loss might be associated with a successful anti-
melanoma immunotherapy.
Cancer cells always express gene product accidentally 
up-regulated due to global gene transcription inbalances.
In the case of virus-induced tumors, viral antigens might 
also be expressed. HPV induced tumors are well known tar-
gets of anti-tumor (in this case, anti-HPV) immune response. 
High immunogenicity of the viral antigens provides an obvi-
ous target to immunostimulator-based tumor therapy. 
The most valuable tumor associated antigens are shared 
tumor antigens that may form the basis of tumor therapy in 
the case of many independent tumors in different patient. The 
future, however, might bring personalized immunotherapy 
directed against tumor clones of individual patients.
The T cell-NK cell functional complementarity 
may help to control MHC-I loss tumor mutants
Cancer cells, by definition, always carry an array of potential 
tumor antigens. The constant selective pressure of the immune 
system favors mutant cancer cell sub-lines that lose MHC-I 
expression (the same phenomenon is also known in the case 
of virus infections). One of the major functions of NK cells 
is the elimination of „MHC-I-loss” mutants. A basic experi-
mental strategy of tumor immunology is vaccination against 
tumor associated antigens. The T cell response induced that 
way increase the selective pressure on the tumor cells, so NK 
activity eliminating the MHC-I loss mutants becomes crucial. 
Importantly, interferon gamma, the defining cytokine of Th1 
cells, simultaneously increases 1) MHC-I expression, 2) CTL 
activity and 3) NK activity, thus facilitating the elimination 
of both MHC-I+ tumor cells, and MHC-I- tumor escape 
mutants. MHC-I loss, due to either lost MHC-I expression 
or beta2 microglobulin expression (Bernal et al. 2012) is 
general phenomenon hindering efficient anti-tumor vaccina-
tion (Slingluff 2007). 
The principles of tumor therapy
Beside surgical resection, malignancies are typically treated 
with radiotherapy or chemotherapy. Radiotherapy, introduced 
in clinical practice in the beginning of the twentieth century, 
uses ionizing radiation to damage the DNA of the tumor 
cells, eventually destroying them. The first generation chemo-
therapeutic agents were alkylating compounds that damage 
the tumor cells’ DNA. Later several classes of chemothera-
peutical agents were discovered, including anti-metabolites, 
i.e., compounds that interfere with DNA synthesis, mitotic 
inhibitors of plant origin, like vinca alkaloids or taxol, DNA 
intercalating agents, as doxorubicin, platins, i.e., platinum 
compounds that behave mostly like alkylating agents, and 
topoisomerase inhibitors (DeVita and Chu 2008). From 1965, 
chemotherapeutic agents have been used in combinations, 
rather than alone. These „classical” chemotherapeutic agents 
are not strictly selective to tumor cells; they act on dividing 
cells, thus causing a wide array of side effects mainly involv-
ing fast-renewing tissues, such as skin, gut epithelium, bone 
marrow, and the immune system. Since immune response is 
mostly beneficial, at least in the early phase of tumorigenesis, 
this last side effect is especially worrisome.
Both radiotherapy and most chemotherapeutical agents 
target rapidly dividing cells, such as bone marrow cells and 
peripheral immune cells. Via inducing massive tumor cell 
necrosis, chemotherapy might also provide danger signals, 
i. e., may also stimulate a type 1, inflammatory, and therefore 
anti-tumoral immune response. In addition, the „immunosup-
pressive” effects of chemo- or radiotherapy target not only the 
effector arm of the immune response, but also the negative 
regulators of the immune effectors, like Treg cells. In conclu-
sion, immunosuppression may, paradoxically, also stimulate 
the anti-tumor effector functions. The literature of this highly 
controversial field is summarized by Zitvogel and coworkers 
Zitvogel et al. (2008). 
Targeted therapy is a new generation therapy that acts 
on molecular processes typical to cancer cells, rather than 
all dividing cells. The most recent developments led to the 
rather artificial category of biological therapy that targets 
tumor cells more specifically. Gleevec® (imatinib mesylate) 
is an enzyme inhibitor of a tumor specific tyrosine kinase. 
Iressa® (gefitinib) targets the epidermal growth factor recep-
tor (EGFR). Sutent® (sunitinib) is a multi-targeted kinase 
inhibitor inhibiting, among others, the vascular endothe-
lial growth factor (VEGF) receptor (Sawyers 2004). Anti-
angiogenic therapy is an especially promising option, since 
its targets are genetically stable endothelial cells responding 
to the major pro-angiogenic factor VEGF, among others, 
by monoclonal antibodies (Sitohy et al. 2012). A different 
class of antibody-like proteins is immunoglobulin Fc region 
containing recombinant proteins. The Anti-VEGF molecule 
Ramucirumab contains a VEGFR domain fused with the hu-
man IgG1 Fc domain, functioning like a VEGF-neutralizing 
IgG1 (Fuchs et al. 2013). 
Personalized tumor therapy, including tumor immuno-
therapy, can now rely on a new generation of minimally 
invasive diagnostic tools, as analysis of circulating tumor cells 
collected from blood samples as “liquid biopsy” (Ligthart 
2013).
Importantly, classic cytotoxic tumor therapy may also 
induce immunogenic cell death (ICD). Tumor cell necrosis/
apoptosis may trigger an effective anti-tumor immune res-
ponse, contributing to the success of the therapy (Kroemer 
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et al. 2013). In other words, anti-tumor immune response is 
inseparable from the therapeutic effect of cytotoxic chemo-
therapy.
Organizing rendezvous between activated 
dendritic cells and tumor antigens
Vaccination and adjuvants
A century old observation is that soluble proteins or pep-
tides alone are not strong immunogens. Immune adjuvants, 
i.e., immunostimulatory components administered together 
with the protein antigen, may substantially increase the 
effectiveness of immunization. The textbook experimental 
adjuvant is Freund’s adjuvant, discovered by the Hungar-
ian immunologist Jules Freund (1890-1960). The main 
component of Freund’s adjuvant is mineral oil, a mixture of 
petroleum-derived alkenes related to paraffin that contains 
heat-inactivated mycobacteria, providing classic danger 
signals. Freund’s adjuvant, however, induces an exceedingly 
violent inflammatory reaction, unacceptable in clinical setup; 
therefore in humans it must be substituted with less aggressive 
compounds. The most widely used vaccine adjuvant, used in 
some of the human clinical trials of tumor antigen immuniza-
tion, is alum (aluminum phosphate and aluminum hydroxide). 
Earlier supposed to be a simple slow release depot, alum is 
now known to activate the NLRP3 inflammasome, resulting 
in inflammatory cytokine production (Eisenbarth et al. 2008; 
Franchi et al. 2009). Further alternatives include squalene, a 
natural triterpene, or saponine (Quillaja saponaria extract). 
They are the main components of the experimental adjuvants 
MF59 or QS21, respectively. Experimental adjuvants may 
also contain synthetic, experimental TLR agonists. Alterna-
tively, the antigen can be „packed” in empty influenza virus 
envelopes (virosomes), which act as a „natural” delivery 
vehicle targeting the immune system. Experimental cancer 
vaccines, including antigens and adjuvants, are reviewed by 
Finn (2003).
One of the first adjuvant ever used, the Mycobacterium 
tuberculosis vaccine strain (Bacillus Calmette-Guérin, BCG), 
has been successfully used in the therapy of bladder cancer 
for decades (Gsponer et al. 2012).
Interestingly, a “new generation adjuvant”, the TLR-7 
agonist Imiquimod (Aldara), when applied directly to skin 
tumors, results in immune activation and tumor rejection. 
Imiquimod, first approved for medical use in 1997, is now 
widely used as a patent applied treatment for basal cell car-
cinoma, squamous cell carcinoma and melanoma (Beutner 
et al. 1999).
Since quite a wide array of tumor-specific antigens is 
known today, selecting a target antigen is generally not a 
problem. Any kind of immunization/vaccination may work 
in this strategy, and, indeed, several different approaches 
are being tried. The simplest approach is administration of a 
protein or peptide antigen plus an adjuvant. In this case, the 
encounter of danger signal, dendritic cell and antigen takes 
place at the site of injection and the draining lymph node 
of the area. Peptide antigens are likewise useable, either as 
more extensive stretches of tumor antigen peptides containing 
several potential epitopes, or shorter peptides directed to the 
(pre-determined) MHC alleles of the patient.
One of the most efficient experimental immunization 
approaches is infection with recombinant vaccinia viruses 
carrying tumor antigens. Genetically engineered pox viruses 
have several advantages. The most important is that the large 
vaccinia virus, engineered to express tumor antigens, might 
also express immunostimulatory cytokines. These possi-
bilities are extensively being studied in mouse models. The 
different modalities of vaccine delivery were compared by 
Bolhassani and coworkers Bolhassani et al. (2011).
Besides the various experimental approaches, peptide 
based vaccines are also licensed for human clinical use. The 
first clinically approved vaccination strategy (Vitespen) is 
based on the use of gp96 heat shock protein (HSP90B1)-
peptide complex purified from resected autologous tumors 
(Wood et al. 2009).
Ex vivo dendritic cell therapy
According to the literature, activated dendritic cells pulsed 
with tumor antigens ex vivo are more effective in inducing 
anti-tumor CTL response than the irradiated tumor cells, 
either with or without adjuvant. In accordance with these 
literature data, we obtained similar results using mouse spleen 
dendritic cells matured in the presence of the inflammatory 
cytokine granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) and labeled with an MHC I binding peptide 
derived from the TRP-1 melanoma differentiation antigen. 
Mice immunized with these “peptide-pulsed” dendritic cells 
triggered a more robust CTL response against the B16 mouse 
melanoma cell line than mice vaccinated by the tumor itself 
(Vizler, unpublished). Analogous approaches are also being 
tested in clinical setup.
Surprisingly, the first FDA approved approach is much 
more complex. Sipuleucel-T (trade name Provenge) is an 
ex vivo dendritic cell therapy for advanced prostate cancer. 
In the first step, dendritic cells are obtained from prostate 
carcinoma patients by leukapheresis. The dendritic cells are 
then treated with a fusion protein composed of a frequently 
expressed prostate tumor antigen, prostatic acid phosphatase 
(PAP) and the pro-inflammatory cytokine GM-CSF. The cells 
are then re-injected in the patient. The company has several 
similar products, based on different tumor antigens, under 
development (Kantoff et al. 2010).
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Adding new receptors to the patient’s immune 
system
Antibody therapy
Tumor specific monoclonal antibodies administered systemi-
cally, as our own antibodies, rely on effector mechanisms of 
the natural immune system. From its introduction in 1997 
(Maloney et al. 1997), antibody therapy is a widely used 
therapeutic option for cancer (Scott et al. 2012). Monoclonal 
antibody therapy is generally based on the use of the most 
“aggressive” immunoglobulin isotype, IgG1. Among the hu-
man IgG immunoglobulin isotypes, IgG1 is the most effective 
in 1) binding to Fc receptors of phagocytes, thus inducing 
phagocytosis of the antibody-labeled cells, 2) binding to Fc 
receptors on NK cells, thus inducing antibody-dependent 
cellular cytotoxicity (ADCC), and 3) triggering the classical 
complement cascade, resulting in both opsonization of the 
tumor cells by membrane-bound complement factors and 
killing by membrane attack complex formation. Until the last 
few years, therapeutic antibodies were created by immuniz-
ing animals, typically mice, with the tumor antigen, then 
hybridomas were created, and monoclonal antibodies of IgG1 
isotype were selected. Today, the majority of monoclonal 
antibodies are genetically engineered; therefore the variable 
part may be generated by different methods, starting from 
different species, while the human Fc part is added in the last 
step. The recombinant antibody is then produced industrially 
by fermentation. 
Various therapeutic antibodies are directed against the 
relatively well known cell surface tumor associated antigens, 
as carcinoembryonic antigen (CEA), epithelial cell adhesion 
molecule (EpCAM), CD19, CD20, and CD22. IgG1 type 
monoclonal antibodies are then able to mark their targets 
for killing by complement dependent lysis, phagocytosis or 
ADCC. An interesting experimental approach relies on pre-
activation of the patients’ NK cells by treatment with agonistic 
antibody directed to the killer cell activating receptor CD137, 
resulting in an enhanced ADCC activity when a subsequent 
antibody treatment is directed to tumor antigens, as CD20 
(Korth et al. 2011).
The effectiveness of these effector mechanisms is, how-
ever, not always sufficient. The killing efficiency of antibodies 
can be enhanced by conjugating them with a lethal “payload” 
(Teicher and Chari 2011). Some examples of these „armed” 
antibodies are Oportuzumab monatox (EpCAM-specific 
single chain variable fragment fused with Pseudomonas 
aeruginosa exotoxin A), Yttrium (90Y) clivatuzumab tet-
raxetan (humanized anti-MUC1 antibody conjugated with 
a radioactive isotope), and Nacolomab tafenatox (mouse 
monoclonal antibody fused with Staphylococcus aureus 
enterotoxin A). 
Antibodies may also be conjugated with cytokines, pro-
viding a targeted delivery of the immunomodulating mol-
ecules. Since the action of cytokines is mostly autokrine and 
parakrine, rather than systemic, this targeting may increase 
the efficiency of the therapy, simultaneously preventing side 
effects of the pleiotropic systemic cytokines. The example 
for this approach is Tucotuzumab celmoleukin (humanized 
anti-EpCAM-IL-2 conjugate).
A further possibility being explored by a number of phar-
maceutical companies is the use of antibodies conjugated with 
chemotherapeutic drugs. This approach might increase the lo-
cal drug concentration, resulting in higher effective dose and 
lower side effect than in the case of classical chemotherapy 
(Zolot et al. 2013).
The main classes of anti-tumor antibodies – the 
example of therapeutic antibodies directed to 
the CD20 tumor associated antigen
First generation monoclonal anti-tumor antibodies were typi-
cally produced in mice. The variable domains of antibodies, 
especially the complementarity determining regions (CDR) 
where the genetic variability concentrates, are, by definition, 
foreign structures that may trigger a host immune response. 
If the antibody is from another species, not just the variable 
region, but the whole IgG molecule can be the target of a 
humoral immune response. Host antibodies recognizing the 
therapeutic antibodies may then eliminate them. Even more 
serious problem is the potential systemic hypersensitivity 
reaction triggered by the repeatedly administered foreign 
antigen.
The solution of this problem can be recombinant antibody 
technology, i.e., swapping of the immunogenic “foreign” 
part of mouse antibody to a much less immunogenic human 
sequence. Some residual immune reactivity might be induced 
even in this case, due to minor differences between the im-
munoglobulin genes of different individuals (immunoglobulin 
allotypes). The non variable part used in these scenarios 
is generally that of the human IgG1 molecule. IgG1 is the 
antibody isotype that triggers host effector mechanism most 
robustly, as this isotype induces the classical pathway of 
complement activation, opsonization and ADCC. 
CD20, a B cell surface molecule frequently expressed 
by B cell leukemias, was the target of the first therapeutic 
antibody approved by the FDA (Maloney et al. 1997). Today 
it is an example of tumor-associated antigens targeted by 
therapeutic antibodies of different generations (Lim et al. 
2010). 
When the Fab domains of the resulting hybrid antibody 
are from the original mouse sequence, the Fc domains are 




When only the essential parts of the mouse antibody, the 
CDR domains are retained, the result is a humanized antibody 
(Example: Ocrelizumab).
The best solution is the use of genetically modified “hu-
manized mice” for immunization and then creation of hybri-
doma cell lines. In these humanized mouse strains, the mouse 
immunoglobulin gene cluster is replaced with a complete 
human immunoglobulin gene cluster. Immunization of these 
mice results in rearrangement of human, rather than mouse 
immunoglobulin gene segments, resulting in fully human 
immunoglobulins (Green 1994; Lonberg 1994) (Example: 
Ofatumumab).
According to the standardized WHO pharmacological 
nomenclature, fully mouse antibodies contain the “-tumo-“ 
subtems (e.g., Tositumomab), chimeric antibodies are called 
“-tuxi-“, (Rituximab), humanized antibodies are called 
“-tuzu-“ (Ocaratuzumab, Ocrelizumab, Obinutuzumab /a 
„glycoengineered” antibody, where even the glycosilation 
pattern is human-like/), and fully human antibodies contain 
the “-tumu-“ subtem (Ofatumumab).
A further variation of the last technology is based on an in 
vitro selection system, rather than on immunization of an ani-
mal. These methods involve creation of a library of variants 
(mutants) of the (preferably human) CDR region sequences, 
followed by a high throughput selection for the (extremely 
rare) high binding affinity variants. The selected sequences 
are then built in the cloned human IgG1 gene. The method 
most widely used for selecting high affinity recombinant im-
munoglobulin variants is phage display.
TcR therapy
A more sophisticated approach is adding T cell receptors, 
rather than immunoglobulins (B cells receptors) to the pa-
tient’s immune system. A direct approach of T cell therapy 
is in vitro activation/expansion, then re-administration of 
tumor-infiltrating lymphocytes (TIL) (Restifo et al. 2012). 
A more complex approach is based on isolating T cells, 
then “arming” them with a tumor-specific T cell receptor by 
transfection, typically using retroviral vectors (Kershaw 2005; 
Restifo et al. 2012). The transfected cells, expressing both the 
original and a transgenic T cell receptor, are then infused into 
the patient. The ex vivo manipulation and genetic modifica-
tion of the – potentially immortal – patient T cells carries the 
risk of malignant transformation, so the genetic modification 
must include the insertion of a suicide gene, typically the 
herpes virus thymidine kinase, which sensitizes the cell to 
the cytotoxic action of the drug acyclovir. Unlike the human 
enzymes, the herpes virus thymidine kinase incorporates the 
chain-terminating nucleotide analog acyclovir in the DNA of 
the transfected cell, thus killing it. 
T cell receptors recognize the target epitopes bound to 
MHC molecules; therefore, they are strictly MHC specific. 
The use of TcR transgenes would not be possible if none 
of the (extremely numerous) MHC-I alleles would be over-
represented in the populations. Luckily, an MHC-I allele, 
HLA-A1, is present in 10-25% of the European population, 
so typically HLA-A1-restricted TcR transgenes are used 
in the experimental therapy, naturally, only in patients pre-
screened for the presence of this allele. Importantly, one of 
the immunodominant peptides of the melanoma-associated 
antigen Melan-A/MART-1 seem to be presented by multiple 
HLA-A alleles (Fleischhauer et al. 1996).
Hybrid immunoglobulin-TcR approaches
An interesting „hybrid” approach is being developed by 
the English pharmaceutical company Immunocore. In their 
system, the tumor antigen-TcR contact is „mimicked” by a 
hybride molecule bridging the MHC-peptide complex on 
tumor cells with the TcR of T cells. The hybrid molecules, 
termed immune-mobilizing monoclonal TCRs against cancer 
(ImmTACs), activate host T cells independently of the speci-
ficity of their endogenous TcR. ImmTACs are comprised of a 
tumor-specific monoclonal TcR fused to a humanized CD3-
specific single-chain antibody variable fragment (scFv). CD3 
is a part of the T cell receptor complex, and its activation by 
agonist covalently coupled Ab mimics the activation through 
the T cell receptor (TcR) by its cognate ligand (Lyddy et al. 
2012).
A similar approach, based on bispecific antibodies, is 
being developed by AMGEN. The Bispecific T Cell En-
gager (BiTE®) Antibodies, analogously to the ImmTACs, 
recognize tumor cell surface antigens and the CD3 molecule 
of the TcR complex, thus redirecting T effector cells (Topp 
et al. 2014). 
Fine-tuning the existing immune response
Administration of immune activating cytokines
Cytokine therapy as cancer therapy has been explored from 
the eighties, and IL-2 and type 1 interferons are licensed for 
clinical use for more than 20 years. Beside IL-2 and inter-
ferons, much effort was concentrated on colony stimulating 
factors (Heberman 1987). Today, type I interferons are the 
most widely used cytokines in tumor therapy, including 
melanoma therapy (Mocellin et al. 2013). Type I interferons 
were first described as anti-viral defense molecules, and the 
first clinical trials with interferons were done in diseases of 
validated, or, at least, hypothesized viral origin (Kirkwood 
and Ernstoff 1984). The mode of action of type I interferons 
in tumor therapy is still not fully understood.
IL-2 has a complex biological role. It activates T cells and 
is also produced by them; therefore it supports T cell prolife-
ration by positive feedback. On the other hand, it is indispens-
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able for the activity of T regulatory (Treg) cells, the main 
negative regulators of cellular immune response (Coventry 
2012). In spite of this pleiotropic effect, IL-2 is successfully 
being used in tumor immunotherapy (Rosenberg 2001).
As a „master regulator” of cellular immune response, 
IL-12 also seemed to be a good candidate for tumor im-
munotherapy. Since it induces interferon-αand activates both 
cytotoxic T cells and NK cells, it seemed to be obvious that its 
effect is based on an enhanced anti-tumor cellular immunity. 
The situation, however, seems to be more complex. IL-12 
induces the release of high amounts of interferon-γ, mostly 
from NK cells. The produced interferon-γ then induces fur-
ther cytokines, including IP-10 (CXCL-10). IP-10, in turn, 
is an effective inhibitor of angiogenesis. In accordance with 
that, the IL-12 dose required for an anti-tumor effect is fre-
quently above the optimal CTL activating level, and tumor 
regression does not necessarily correlates with an increased 
anti-tumor CTL or NK response (Vizler et al. 1998). On the 
other hand, animal studies showed that the effectiveness of 
IL-12 treatment relies on the production of type I interferons. 
Clinical studies on its systemic use were not encouraging, 
but its application for local combination therapy is still under 
investigation (Lasek 2014).
Beside systemic treatments with recombinant proteins, 
cytokine gene therapy, typically based on transfection of 
the tumor cells in vitro or in vivo, has also been tested in 
animal models, and later in clinical setup. Although several 
(or maybe most) cytokines were able to induce rejection of 
transfected tumor grafts via activating different anti-tumor 
effector mechanisms, the treatments did not prove to be 
effective against established tumors or metastases, so this 
approach has been mostly abandoned (Nanni et al. 1999; 
Nagy et al. 2003).
T cell activation via agonistic antibodies 
targeting co-stimulatory molecules
Although, on a purely theoretical basis, application of ago-
nistic monoclonal antibodies seemed to be a promising op-
tion, the first trial ended with a disaster, probably hindering 
further similar studies. The rationale was that TGN1412, a 
humanized agonist antibody directed to the major T cell co-
stimulatory molecule CD28, will trigger an effective immune 
response against tumors. Unfortunately, some of volunteers 
participating in the phase I study suffered life threatening side 
effect, probably because of systemic immune hyper-reactivity 
causing edema and multi-organ dysfunction. Retrospective 
studies suggested that the side effects, absent in animal ex-
periments, might be due to the activation of memory T cells, 
much more frequent in humans that in laboratory animals 
raised under „sterile” conditions (Suntharalingam 2006).
Relieving tumor-induced immunosuppression by 
antibodies blocking negative regulators of the T 
cell response
Checkpoint inhibitors targeting negative regulators of T cell 
responses, including the anti-tumor T cell response, i.e., the 
Table 1. The main targets of tumor immunotherapy
Immune mechanism Defect in cancer Potential therapy
Phagocytosis Lack of triggering signals Cytotoxic chemotherapy for inducing immunogenic cell death (ICD).
Ex vivo tumor cell phagocytosis by autologous dendritic cells.
Ex vivo transduction of dendritic cells by tumor antigens.
Dendritic cell activation 
via pattern recognition 
receptors
Lack of danger signals Local application of danger signals (natural or synthetic TLR agonists).
Ex vivo dendritic cell activation by danger signals or inflammatory cytokines.
Infection with bacteria driving Th1 differentiation. 
Co-stimulatory ligand 
expression, dominant over 
inhibitory ligand expression 
Tumor-induced immunosup-
pression
Agonistic monoclonal antibodies targeting stimulatory T cell co-receptors (failed 
attempt).
Blocking monoclonal antibodies targeting inhibitory T cell co-receptors (the most 
promising approach of our days).
Primary T cell activation Low abundance of tumor an-
tigens and/or co-stimulators
Vaccination with tumor antigen.
Vaccination with tumor antigen-presenting dendritic cells.
Vaccination with genetically modified viruses expressing tumor antigens.
T cell expansion, CTL killing Insufficient number of tumor-
specific CTL
Immunostimulatory cytokine administration.
Adoptive transfer of in vitro expanded T cells. 
Relieving tumor induced immunosuppression by cytokine-neutralizing antibodies.
“Hybrid” TcR activating molecules.
Tumor-specific antibody 
production
Insufficient amount or killing 
efficacy of antibodies
Tumor-specific IgG1 monoclonal antibody administration.
„Armed” tumor-specific monoclonal antibody administration.
NK killing of MHC-I nega-
tive tumor escape mutants
Insufficient NK activity NK cell activation by TLR ligands, killer activating receptor agonists, or HSP induc-
tion.
Adoptive transfer of in vitro expanded (allogeneic) NK cells.
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CTLA-4 and the PD-1 receptors, might be the most promising 
of all the tested approaches.
The T cell surface molecule CTLA-1 is one of the major 
negative feedback regulators of T cell response. Activation 
and inhibition of the CTLA-1 signal offer therapeutical possi-
bilities in autoimmunity and cancer, respectively. Ipilimumab 
(Yervoy), a fully human IgG1 monoclonal antibody, has been 
successfully used in both cases (Hodi et al. 2010). In addition 
to melanoma, Ipilimumab is under clinical trials for non-small 
cell lung carcinoma, small cell lung cancer, bladder cancer, 
and prostate cancer.
Another T cell surface protein of the CD28/CTLA-4 fami-
ly of T cell regulators, PD-1, has been the target of successful 
immunomodulatory antibody therapy (Topalian et al. 2012). 
The monoclonal antibody treatment, disrupting the contact 
of PD-1 with its ligands PD-L1 and PD-L2, has been shown 
to be more effective than dacarbazine, the first choice drug 
in melanoma chemotherapy (Robert et al. 2014). The PDF1 
blocking antibodies, Pembrolizumab or Nivolumab, function 
by relieving immunosuppression in cancer. Since PD-L1 and 
PDL2 are widely expressed in tumors of different histological 
origin, this is one of the most interesting discoveries of the 
last years. The antibody is fully human monoclonal antibody. 
In these cases, in contrast with treatments targeting the tumor 
cells themselves, the goal is receptor blocking without kill-
ing the immune cells carrying them, so IgG4 antibodies are 
optimal.
The high efficacy of these immunostimulating antibodies 
is mirrored by their immune activation-related side effects, 
including meningitis, pneumonitis, vitiligo, colitis, hepatitis, 
hypophysitis, and thyroiditis (Topalian et al. 2012; Voskens 
et al. 2013). The cost-benefit balance of the treatments, ne-
vertheless, remains positive.
Ex vivo expansion of anti-tumor cytotoxic T cells 
and NK cells
Another, decades old, but still experimental strategy for 
enhancing the anti-tumor immunity is in vitro expansion 
of effector cells. Although the proper type protective host 
immune response is frequently induced by malignant cells, 
the magnitude of the response is not always sufficient for 
Figure 1. A brief summary of immunotherapy approaches licensed for clinical use or currently undergoing Phase III clinical trials. The trade 
names or, in some cases, scientific names of example therapeutic agents are given in parentheses. Classification of the current immunotherapies 
in clinical or experimental phase is provided by Galluzzi et al. (2014). The immune checkpoint blocking approaches are summarized by Kyi and 
Postow (2014). The known tumor antigens are classified by Novellino et al. (2005).
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elimination of the tumor. In such cases, collection and ex vivo 
expansion of the immune cells offers a solution. This type of 
therapy generally starts with the isolation of autologous T 
cells from the circulation, or from excised tumors or biopsies 
(tumor-infiltrating lymphocytes, TIL) (June 2007). The cells 
are then expanded in vitro using the proper cytokine cocktail, 
then re-infused into the patient, either alone, or together with 
immune-activating cytokines. Importantly, immunotherapy 
with in vitro expanded T cells gave rise to even more complex 
approaches, like those based on T cells transfected with a 
tumor-specific T cell receptor (Rosenberg et al. 2008).
As T cells, NK cells can also be expanded in vitro for 
adoptive transfer. While clinical studies with autologous NK 
cells typically gave negative results, allogeneic NK cells had 
a therapeutic effect (Miller et al. 2005).
Interestingly, while the killer inhibitor receptor (KIR) 
repertoire of NK cells of individuals seem to be fixed (i.e., 
dictated by the genetical background, especially MHC-I al-
leles), the killer activating receptor (KAR) composition seems 
to be determined by environmental factors (“education”). This 
fact raises the possibility of a therapeutic exploitation of the 
potentially tumor-specific KAR inducibility and variability 
(Vivier et al. 2012; Horowitz 2013).
Harnessing infection-related immunomodulation 
Since infections provide danger signals, a natural assump-
tion is that infection might help to enhance the otherwise 
weak anti-tumor immune response, thus fighting cancer. 
The seminal discovery of William Coley opening the way 
for immunotherapy predated the birth of immunology. Fol-
lowing case reports of patients who recovered from cancer 
following erysipelas (caused by Streptococcus pyogenes 
infection), Coley reproduced the phenomenon by injecting 
cancer patients with S. pyogenes and Serratia marcescens, 
first in living form, later as dead bacteria (Coley’s toxin, or 
Coley’s vaccine, from about 1893). Although the treatment 
has some success, it was replaced by the more reproducibly 
effective radiotherapy. Nevertheless, from time to time, the 
concept resurfaces in different forms.
Another interesting (and robust) support for this theory 
comes from epidemiological data. In 2003, a large clinical 
study performed by EORTC (European Organization for 
Research and Treatment of Cancer) provided unexpected 
evidence for a positive effect of microbial infection in cancer. 
Krone et al. showed that febrile infections or vaccinations 
with Bacillus Calmette Guerin or vaccinia virus in early 
childhood significantly decreased the incidence of malignant 
melanoma (Krone et al. 2003; Krone et al. 2005).
The third line of evidence comes from clinical data of 
patients treated with chemotherapy. According to these 
data, chemotherapy decreases the resistance to opportunistic 
pathogenic bacteria that, in turn, induce a classic Th1 type, 
inflammatory immune response. This „re-education” of the 
immune system by pathogens, diverted by the immuno-
modulatory effect of tumors, is beneficial. The hypothesis is 
supported by experiments where elimination of opportunistic 
pathogens compromised the effectiveness of chemotherapy 
(Iida et al. 2013).
In addition to their immunological effect, different bac-
teria were shown to display specific homing into tumors 
(Wei et al. 2008). Several attempts are made to harness this 
effect, either for tumor killing, typically by Clostridium 
strains (Zwagerman 2014), or for tumor specific delivery of 
a pharmacological payload, typically by Salmonella strains 
(Kazmierczak et al. 2015).
Besides bacteria, different oncolytic viruses are under 
Phase II or Phase III clinical trials, including GM-CSF ex-
pressing herpes simplex virus Talimogene laherparepvec or 
OncoVEX GM-CSF (Hu et al. 2006); Oncorine (H101), a ge-
netically modified adenovirus targeting P53 deficient cancer 
cells (Garber 2006); the reovirus-based Reolysin (Sei et al. 
2009); or JX-594, a GM-CSF expressing vaccinia poxvirus 
(Heo et al. 2013).
Conclusions
The main types of immune mechanisms deficient in cancer, 
as well as the therapeutical strategies targeting them are sum-
marized in Table 1. Immunotherapy relies on manipulating 
the delicate balance of immune regulation, therefore, its use 
might have a “price” to pay, in the form of side effects related 
to immune reactivity (Caspi 2008). Nevertheless, immuno-
therapy is now coming to age (Galluzzi et al. 2014). This 
promising field is in constant growth, with a wide array of 
strategies that are routinely used in medical practice, or are at 
the threshold of clinical use. The most important approaches 
in clinical use or in Phase III clinical trials are summarized 
in Figure 1.
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